Avin Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.12 M
- Company Age 3 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 55.60%
- Profit Growth 89.41%
- Ebitda 14507.12%
- Net Worth 3639.58%
- Total Assets -5.87%
About Avin Drugs
Avin Drugs Private Limited (ADPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 12 April 2021 (Three years and nine months 22 days old ). Its registered office is in Jaipur, Rajasthan, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.12 M, as per Ministry of Corporate Affairs (MCA) records.
Ashish Mathur, Sunita Mathur, and Yash Jain serve as directors at the Company.
Company Details
-
Location
Jaipur, Rajasthan, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24296RJ2021PTC074513
-
Company No.
074513
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
12 Apr 2021
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Jaipur
Industry
Who are the key members and board of directors at Avin Drugs?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashish Mathur
|
Director | 12-Apr-2021 | Current |
|
Sunita Mathur
|
Director | 12-Apr-2021 | Current |
|
Yash Jain
|
Director | 01-Mar-2022 | Current |
Financial Performance of Avin Drugs.
Avin Drugs Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 55.6% increase. The company also saw a substantial improvement in profitability, with a 89.41% increase in profit. The company's net worth Soared by an impressive increase of 3639.58%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Avin Drugs?
Unlock access to Avin Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Jinji Delights Private LimitedYash Jain is a mutual person
-
Uniclan Hygiene Private Limited
Yash Jain is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Avin Drugs?
Avin Drugs has a workforce of 0 employees as of Mar 25, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Avin Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Avin Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.